Endometrial Cancer Market Size, Share, Trends, Growth and Forecast 2034

Endometrial Cancer Perspective:

What is the anticipated size of the endometrial cancer market during the projection period?

The global endometrial cancer market size was worth around USD 31.09 billion in 2024 and is predicted to grow to around USD 51.15 billion by 2034 with a compound annual growth rate (CAGR) of roughly 5.60% between 2025 and 2034.

Request Free SampleRequest Free Sample

Key Insights:

• As per the analysis shared by our research analyst, the global endometrial cancer market is estimated to grow annually at a CAGR of around 5.60% over the forecast period (2025-2034)
• In terms of revenue, the global endometrial cancer market size was valued at around USD 31.09 billion in 2024 and is projected to reach USD 51.15 billion by 2034.
• The market is projected to grow at a significant rate due to the rising prevalence of the condition across the globe.
• Based on the type of cancer, the endometrial carcinoma segment is growing at a high rate and will continue to dominate the global market, as per industry projections
• Based on the type of therapy, the immunotherapy segment is anticipated to command the largest market share.
• Based on the diagnosis method, the biopsy segment is expected to lead the market growth trends.
• Based on region, Europe is projected to dominate the global market during the forecast period.

Endometrial Cancer Market: Overview

Endometrial cancer is caused by abnormal growth of cells in the uterus. It is a reproductive organ where fetal development takes place. Endometrial cancer begins in the endometrium. It is a layer of cells forming the uterus lining. According to official reports, endometrial cancer is also known as uterine cancer. However, there are other types of endometrial cancer as well, including uterine sarcoma. One of the primary symptoms of endometrial cancer is irregular vaginal bleeding, which is also the main reason for early detection of this cancer form. Removal of the uterus can cure endometrial cancer.

During the forecast period, a rising female population, increasing prevalence of disease, heightened patient awareness, and a surge in healthcare expenditure are expected to drive the endometrial cancer market. The industry is projected to face growth limitations due to the high cost of treatment, lack of effective healthcare in low and middle-income economies, and delayed diagnosis.

Impact of the USA-Israel and Iran War on the Endometrial Cancer Market:

The USA-Israel and Iran war is projected to affect medical travel, especially in Middle Eastern countries. In addition, disruptions in the supply chain for pharmaceutical products and medical equipment will further affect market revenue. In the long run, industry players are expected to increase domestic production, expand business operations in new markets, and adopt novel distribution channels for sustained growth.

Endometrial Cancer Market: Dynamics

Growth Drivers

How will the rising prevalence of the disease influence the endometrial cancer market?

The global endometrial cancer market is expected to be driven by the rising prevalence of the condition across the globe. According to the American Cancer Society, some of the prominent risk factors for endometrial cancer include long-term exposure to the sun, smoking, and family history. In addition, undergoing estrogen-replacement therapy, no pregnancies, obesity, polycystic ovary syndrome (PCOS), estrogen-secreting ovarian tumors, and the number of menstrual periods in a lifetime are some of the other reasons that can cause uterine cancer. Around 3% of women are expected to be diagnosed with endometrial cancer once in their lifetime, thus driving demand for effective diagnostic tools and subsequent medical therapies.

Ongoing investments in cancer research and increased healthcare expenditure will fuel market expansion

Cancer research over the last decade has increased significantly worldwide. The growing burden of the disease on the existing healthcare infrastructure has accelerated cancer research projects. For instance, in a recent event, the US Department of Defense (DoD) authorized USD 10 million for an endometrial cancer research program through the National Defense Appropriations Act (NDAA). Furthermore, the global endometrial cancer market is projected to benefit from the surge in healthcare expenditure facilitated by the construction of new healthcare and diagnostic facilities.

Restraints

How will high treatment costs shape the endometrial cancer market during the forecast period?

The global endometrial cancer industry is projected to be restricted due to the high cost of treatment and diagnosis. According to market analysis, advanced treatments such as immunotherapies and targeted medicines can cost more than USD 100,000 even in countries with robust infrastructure. Low and middle-income economies and nations currently under social-political turmoil are expected to face growth restrictions during the forecast period.

Opportunities

Technological advancements to improve diagnostic procedures will create growth opportunities

The global endometrial cancer industry is anticipated to generate growth opportunities due to technological advancements in diagnostic procedures. Increasing use of advanced engineering solutions such as Artificial Intelligence (AI) and information processing applications is expected to shape industry growth trends in the coming years. In April 2026, Utepreva LLC, a U.S.-based medical device company, announced the launch of the Utepreva Endometrial Sampler. It is a US Food & Drug Administration (FDA 510(k)-cleared, patented, single-use endometrial sampling device. The tool is designed to allow tissue capture and facilitate early diagnostic evaluation of endometrial cancer.

In April 2026, PinkDx, a US-based biotechnology/diagnostics company, announced a new painless and accurate test for endometrial cancer diagnosis. As per the company's claims, the diagnostic method has been under clinical trial at 12 renowned medical centers. It will involve sending vaginal swabs to the company’s lab, and the results will be processed in the next 2 weeks.

Challenges

What are the prominent challenges affecting the endometrial cancer industry?

The global endometrial cancer industry is anticipated to be challenged by a lack of effective infrastructure, the absence of comprehensive medical reimbursement policies, and limited patient awareness. Market players must focus on establishing robust medical care infrastructure in emerging economies to elevate brand value and amplify total revenue. Until these parameters are taken care of, the market will continue to register limited growth trends.

Endometrial Cancer Market: Report Scope

Endometrial Cancer Market: Segmentation

The global endometrial cancer market is segmented based on type of cancer, type of therapy, diagnosis method, and region.

Why will the endometrial carcinoma segment deliver a faster CAGR in the endometrial cancer industry revenue during the forecast period?

Based on the type of cancer, the global market segments are uterine sarcomas, endometrial carcinoma, and others. In 2024, the highest growth was listed in the endometrial carcinoma segment, accounting for 74% of the total revenue. It is expected to grow at a CAGR of 8% during the forecast period since endometrial carcinoma is the most common form of uterine cancer.

Which will be the fastest-growing type of therapy during the forecast period in the endometrial cancer market?

Based on the type of therapy, the global endometrial cancer industry is divided into chemotherapy, radiation therapy, immunotherapy, targeted therapies, and others. In 2024, the highest growth was listed in the chemotherapy segment, contributing up to 46% of the final revenue. During the forecast period, immunotherapy is projected to grow at a faster CAGR of 15.1% since it delivers an improved survival rate and helps improve quality of life.

Why will the biopsy segment continue to lead the endometrial cancer industry in the coming years?

Based on the diagnosis method, the global market divisions are pelvic ultrasound, biopsy, CT scan, hysteroscopy, and others. In 2024, the biopsy segment was the leading revenue generator. It accounted for 52% of the global revenue and is anticipated to grow at a CAGR of 7.18% during the forecast period. Ongoing advancements toward minimally invasive techniques for biopsies will aid segmental growth in the future.

Endometrial Cancer Market: Regional Analysis

Why is Europe projected to lead the endometrial cancer market during the forecast period?

The global endometrial cancer market is currently led by Europe. In 2024, it accounted for 46% of the global revenue. It will grow at a CAGR of 6.11% during the forecast period. The presence of an affordable and comprehensive cancer medical care industry, along with prominent pharmaceutical companies, will drive regional growth trends. In addition, the rising prevalence of endometrial cancer and improved patient awareness will further influence accelerated growth across Europe.

How is Asia-Pacific expected to perform in the endometrial cancer market during the projection period?

Asia-Pacific is projected to emerge as the fastest-growing region in the endometrial cancer market with a CAGR of 9.4% during the forecast period. In 2024, it accounted for 26% of the global revenue. Expansion of the regional healthcare industry, rising development of indigenous endometrial cancer diagnosis tools, and increased demand for targeted therapies will work in favor of the regional market. Furthermore, government support encouraging cancer research will aid in improved revenue across the Asia-Pacific

Endometrial Cancer Market: Competitive Analysis

The global endometrial cancer market is led by players like:

• Johnson & Johnson
• Bristol Myers Squibb
• Pfizer
• Roche
• Novartis
• AbbVie
• Takeda Pharmaceutical Company
• Gilead Sciences
• Merck & Co.
• GlaxoSmithKline
• Amgen
• Sanofi
• AstraZeneca
• BeiGene
• Eli Lilly and Company

What are the latest key trends in the endometrial cancer market?

Shift away from chemotherapy

The introduction of new targeted therapies and immunotherapy in cancer care has led to an increased shift away from chemotherapy. Use of PD-1/PD-L1 inhibitors in cancer therapies is becoming a standard solution since they deliver improved outcomes.

Remote diagnosis and treatment

Rising integration of telehealth technologies, such as remote diagnosis and therapies, is emerging as a prominent market trend. It ensures access to quality medical care across remote locations, thus encouraging market expansion.

The global endometrial cancer market is segmented as follows:

By Type of Cancer

• Uterine Sarcomas
• Endometrial Carcinoma
• Others

By Type of Therapy

• Chemotherapy
• Radiation Therapy
• Immunotherapy
• Targeted Therapies
• Others

By Diagnosis Method

• Pelvic Ultrasound
• Biopsy
• CT Scan Hysteroscopy
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America